Surgery is the gold standard, GLP-1s are all the rage—whether a head-to-head study is needed depends on who you ask.

Laxxon Medical reports positive results from pilot PK study of innovative oral GLP-1 agonist weight loss tablet, LXM.2 ...

GLP-1 drug users initially spend less on groceries, but that levels out over the next year, shows Circana's analysis of food ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

Mounjaro, like other GLP-1 drugs, carries potential side effects, including nausea, vomiting, dehydration, and hypoglycaemia ...

Unless you have no TV or Internet, you’ve likely heard of the GLP-1 craze – glossy commercials and ads featuring people ...

Ozempic doesn’t just reduce weight. Research shows GLP-1s also changes how much people spend on food, and the types of food ...

H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on VKTX stock, giving a Buy rating on January 9.Stay Ahead of the ...

Novo NOrdisk (NVO) stock drops as Medicare selects 15 additional Part D drugs including its weight loss drug Wegovy for ...

Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a ...

When drugmakers pulled the weight-loss drug fen-phen off the market in 1997, my mom was devastated. Not because the FDA ...